EGFR and non-small cell lung carcinoma: Fortunately, identification of oncogenic driver mutations in ADC patients, as well as the rapid development of targeted therapeutic agents, such as epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), have greatly enriched the arsenal against NSCLC and provided patients with better therapeutic outcomes and milder side effects (Wang et al. 2021; Liu et al. 2023).